In the hunt for a remedy, when the baton is passed from dedicated academic scientists to an innovative company to trusted community advocates, outcomes for society can be especially powerful.

A common medication used to treat HIV and hepatitis B may offer unexpected protection against Alzheimer's disease.

Gilead Sciences agreed to pay $202 million to the U.S. government and various states to settle claims it used speaker ...

In the face of a fear of loss of funds for ending the HIV/AIDS epidemic, activists in New Jersey walked to raise money.

An ambitious plan to stop the global threat of AIDS has been derailed. But many are hopeful that progress can be salvaged.

Seven percent of 108 healthy volunteers reported urticaria; unresolved urticaria persisted at 12 months in four participants.

"I was told I had a virus with no cure and between three and nine months to live." HIV activist Jonathan Blake believes he ...

"Many healthcare providers who received these improper kickbacks then prescribed the Gilead HIV Drugs," the office said. "As a result, federal healthcare programs paid millions of dollars in ...